Yvonne Greenstreet Sells 5,219 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Alnylam Pharmaceuticals Trading Up 0.2 %

NASDAQ ALNY opened at $253.74 on Friday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market cap of $32.73 billion, a P/E ratio of -96.85 and a beta of 0.39. The stock has a 50 day simple moving average of $271.93 and a two-hundred day simple moving average of $240.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the company earned $1.15 EPS. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% compared to the same quarter last year. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALNY. TD Cowen lifted their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Citigroup lifted their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Scotiabank lifted their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $29,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.